Government-Owned Inventions; Availability for Licensing, 34020-34021 [E7-11825]
Download as PDF
<![CDATA[
34020
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
Dated: June 13, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer,Office of Technology
Transfer,National Institutes of Health.
[FR Doc. E7–11824 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
rwilkins on PROD1PC63 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
NUP98–HOXD13 Transgenic Mice
Description of Technology:
Myelodysplastic syndrome (MDS) is
collection of closely related blood
diseases that arise in the bone marrow
characterized by anemia, neutropenia,
and thrombocytopenia resulting from
hematopoietic stem cell disorders. A
variety of genetic aberrations have been
associated with MDS, including
chromosomal translocations of the
NUP98 gene. The only current curative
therapy for MDS is allogeneic bone
marrow transplant. Without bone
marrow transplant, patients either die of
progressive pancytopenia or following
transformation of MDS to acute myeloid
leukemia. Progress in understanding
and treating MDS has been hampered by
a lack of an animal model that
accurately recapitulates all of the
features of human MDS. Utilizing a
NUP98-HOXD13 (hereafter NHD13)
fusion gene, a mouse model was
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
developed to elucidate the biology of
MDS. Genetically engineered mice that
express an NHD13 transgene display all
of the phenotypic features of MDS
including peripheral blood cytopenia,
bone marrow dysplasia, and
transformation to acute leukemia. These
mice provide an accurate preclinical
model for MDS.
Applications: Model to study MDS
and evaluate MDS therapy.
Market: 15,000–20,000 new cases of
MDS are diagnosed in the U.S.; 80–90%
of patients are older than 60 years old.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Peter D. Aplan et al. (NCI).
Publications:
1. YW Lin et al. Notch1 mutations are
important for leukemic transformation
in murine models of precursor-T
leukemia/lymphoma. Blood. 2006 Mar
15;107(6):2540–2543.
2. YW Lin et al., NUP98-HOXD13
transgenic mice develop a highly
penetrant, severe myelodysplastic
syndrome that progresses to acute
leukemia. Blood. 2005 Jul 1;106(1):287–
295.
Patent Status: HHS Reference No. E–
071–2007/0—Research Tool.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Leukemia Biology Section, Genetics
Branch, National Cancer Institute is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
NHD13 mouse model. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Identification of Ovarian Cancer Tumor
Markers and Therapeutic Agents
Description of Technology: Germline
mutations of BRCA1 and BRCA2 tumor
suppressor genes are responsible for
5%–10% of all epithelial ovarian
cancers. However, little is known about
the molecular mechanisms involved in
BRCA1 and/or BRCA2 mutationassociated (termed BRCA-linked)
ovarian carcinogenesis. To elucidate
their pathways, microarrays were used
to compare gene expression patterns in
ovarian cancers associated with BRCA1
or BRCA2 mutations with gene
expression patterns in sporadic
epithelial ovarian cancers to identify
patterns common to both hereditary and
sporadic tumors. As a result of this
analysis, genes that are upregulated in
ovarian cancer were identified.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Approximately two-thirds of the
sequences identified were previously
known genes, while approximately onethird were expressed sequence tags,
representing sequences that are cloned
and identified but not yet characterized.
Eighty-three genes were over-expressed
in 50% of all tumors and these overexpressed sequences may be used as
markers for ovarian cancer and/or
targets for therapy.
Applications: Method to diagnose
ovarian cancer; Method to treat ovarian
cancer with therapeutics that target
ovarian biomarkers; Ovarian cancer
therapeutics that inhibit ovarian cancer
markers such as siRNA.
Market: Estimated 180,000 new cases
of breast cancer in the U.S. in 2007;
Estimated 41,000 deaths due to breast
cancer in the U.S. in 2007.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Amir Jazaeri (NCI), Edison
T. Liu (NCI), et al.
Publications:
1. AA Jazaeri et al. BRCA1-mediated
repression of select X chromosome
genes. J Transl Med. 2004 Sep
21;2(1):32.
2. AA Jazaeri et al. Molecular
determinants of tumor differentiation in
papillary serous ovarian carcinoma. Mol
Carcinog. 2003 Feb;36(2):53–59.
3. AA Jazaeri et al. Gene expression
profiles of BRCA1-linked, BRCA2linked, and sporadic ovarian cancers. J
Natl Cancer Inst. 2002 Jul 3;94(13):990–
1000.
Patent Status: U.S. Provisional
Application No. 60/357,031 filed 13 Feb
2002 (HHS Reference No. E–310–2001/
0–US–01); PCT Patent Application No.
PCT/US2003/046888 filed 13 Feb 2003
(HHS Reference No. E–310–2001/0–
PCT–02); U.S. Patent Application No.
10/505,680 filed 12 Aug 2004 (HHS
Reference No. E–310–2001/0–US–03).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Tumor Markers in Ovarian Cancer
Description of Technology: Ovarian
cancer is one of the most common forms
of neoplasia in women. Although
advanced ovarian cancer has only a 20–
30% survival rate, an estimated 90% of
cases are effectively treated when
detected early. However, few symptoms
are associated with early ovarian cancer,
and approximately 25% of ovarian
cancer cases are diagnosed before it
metastasizes. Utilizing SAGE analysis, a
unique set of ovarian cancer biomarkers
has been identified that are highly
expressed in ovarian epithelial tumor
E:\FR\FM\20JNN1.SGM
20JNN1
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
cells in comparison to normal ovarian
epithelial cells. A better knowledge of
the mechanisms underlying ovarian
tumorigenesis will likely result in the
development of novel approaches for
the diagnosis and therapy of this deadly
disease.
Applications: Method to diagnose
ovarian cancer; Methods to treat
patients with compositions that inhibit
ovarian biomarkers such as siRNA.
Market: Ovarian cancer is the fourth
most common form of cancer in the
U.S.; Ovarian cancer is three times more
lethal than breast cancer; 22,430 new
cases of ovarian cancer expected in
2007; 15,280 ovarian cancer deaths in
the U.S. in 2007.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Patrice J. Morin et al. (NIA).
Related Publications:
1. KJ Hewitt, R Agarwal, PJ Morin.
The claudin gene family: expression in
normal and neoplastic tissues. BMC
Cancer. 2006 Jul 12;6:186.
2. PJ Morin. Claudin proteins in
human cancer: promising new targets
for diagnosis and therapy. Cancer Res.
2005 Nov 1;65(21):9603–9606.
3. R Agarwal, T D’Souza, PJ Morin.
Claudin–3 and claudin–4 expression in
ovarian epithelial cells enhances
invasion and is associated with
increased matrix metalloproteinase–2
activity. Cancer Res. 2005 Aug
15;65(16):7378–7385.
4. CD Hough, CA Sherman-Baust, ES
Pizer, PJ Morin. Use of SAGE to study
gene expression in ovarian cancer.
American Association for Cancer
Research, 9th Annual Meeting, April
10–14, 1999, Philadelphia,
Pennsylvania.
Patent Status: U.S. Provisional
Application No. 60/194,336 filed 03 Apr
2000 (HHS Reference No. E–138–2000/
0–US–01); PCT Patent Application No.
PCT/US2001/10947 filed 03 Apr 2001,
which published as WO 01/75177 on 11
Oct 2001 (HHS Reference No. E–138–
2000/0–PCT–02); U.S. Patent
Application No. 10/257,021 filed 03 Oct
2002 (HHS Reference No. E–138–2000/
0–US–03)
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Dated: June 8, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer,Office of Technology
Transfer,National Institutes of Health.
[FR Doc. E7–11825 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Construction of Recombinant
Baculoviruses Carrying the Gene
Encoding the Major Capsid Protein,
VP1, From Calicivirus Strains
(Including Norovirus Strains Toronto,
Hawaii, Desert Shield, Snow Mountain,
and MD145–12)
Description of Technology: The
noroviruses (known as ‘‘Norwalk-like
viruses’’) are associated with an
estimated 23,000,000 cases of acute
gastroenteritis in the United States each
year. Norovirus illness often occurs in
outbreaks, affecting large numbers of
individuals, illustrated recently by wellpublicized reports of gastroenteritis
outbreaks on several recreational cruise
ships and in settings such as hospitals
and schools. Norovirus disease is clearly
important in terms of medical costs and
missed workdays, and accumulating
data support its emerging recognition as
important agents of diarrhea-related
morbidity.
Because the noroviruses cannot be
propagated by any means in the
laboratory, an important strategy in their
study is the development of molecular
biology-based tools. This invention
reports the development of recombinant
baculoviruses carrying the capsid gene
from several caliciviruses associated
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
34021
with human disease. Growth of these
baculovirus recombinants in insect cells
results in the expression of virus-like
particles (VLPs) that are antigenically
indistinguishable from the native
calicivirus particle. These VLPs can be
purified in large quantities for use as
diagnostic reagents and potential
vaccine candidates.
Inventors: Kim Y. Green, Judy F. Lew,
Adriene D. King, Stanislav V.
Sosnovtsev, Gael M. Belliot (NIAID).
Publication: An example of the
application of these materials is further
described in KY Green et al., ‘‘A
predominant role for Norwalk-like
viruses as agents of epidemic
gastroenteritis in Maryland nursing
homes for the elderly,’’ J. Infect. Dis.
2002 Jan. 15;185(2):133–146.
Patent Status: HHS Reference No. E–
198–2003/0—Research Material.
Licensing Status: The materials
embodied in this invention are available
nonexclusively through a biological
materials license.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity:
The Laboratory of Infectious Diseases,
NIAID, NIH, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize norovirus VLP antigens.
Please contact Kim Y. Green at
kgreen@niaid.nih.gov for more
information.
Full-Length cDNA Clone Representing
the Consensus Sequence of the RNA
Genome of a Human Norovirus (strain
MD145–12) That Encodes Biologically
Active Proteins
Description of Technology: The
invention provides for a full-length
cloned cDNA copy of the RNA genome
of a predominant norovirus strain
(Genogroup II.4) designated MD145–12
that was associated with human
gastrointestinal illness. The noroviruses,
which were formerly known as
‘‘Norwalk-like’’ viruses are estimated to
cause 23 million cases of acute
gastroenteritis in the USA each year.
The virus has been designated into
category B of the CDC biodefenserelated priority pathogens because it can
be used as an agent of bioterrorism. The
subject cDNA clone of the virus encodes
proteins of the MD145–12 strain that,
when expressed in vitro, exhibit
properties that would be expected from
those produced by the original
infectious virus. This cDNA clone is
presently the only source to obtain
norovirus proteins to facilitate studies
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Pages 34020-34021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11825]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
NUP98-HOXD13 Transgenic Mice
Description of Technology: Myelodysplastic syndrome (MDS) is
collection of closely related blood diseases that arise in the bone
marrow characterized by anemia, neutropenia, and thrombocytopenia
resulting from hematopoietic stem cell disorders. A variety of genetic
aberrations have been associated with MDS, including chromosomal
translocations of the NUP98 gene. The only current curative therapy for
MDS is allogeneic bone marrow transplant. Without bone marrow
transplant, patients either die of progressive pancytopenia or
following transformation of MDS to acute myeloid leukemia. Progress in
understanding and treating MDS has been hampered by a lack of an animal
model that accurately recapitulates all of the features of human MDS.
Utilizing a NUP98-HOXD13 (hereafter NHD13) fusion gene, a mouse model
was developed to elucidate the biology of MDS. Genetically engineered
mice that express an NHD13 transgene display all of the phenotypic
features of MDS including peripheral blood cytopenia, bone marrow
dysplasia, and transformation to acute leukemia. These mice provide an
accurate preclinical model for MDS.
Applications: Model to study MDS and evaluate MDS therapy.
Market: 15,000-20,000 new cases of MDS are diagnosed in the U.S.;
80-90% of patients are older than 60 years old.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Peter D. Aplan et al. (NCI).
Publications:
1. YW Lin et al. Notch1 mutations are important for leukemic
transformation in murine models of precursor-T leukemia/lymphoma.
Blood. 2006 Mar 15;107(6):2540-2543.
2. YW Lin et al., NUP98-HOXD13 transgenic mice develop a highly
penetrant, severe myelodysplastic syndrome that progresses to acute
leukemia. Blood. 2005 Jul 1;106(1):287-295.
Patent Status: HHS Reference No. E-071-2007/0--Research Tool.
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The Leukemia Biology Section,
Genetics Branch, National Cancer Institute is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the NHD13 mouse
model. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Identification of Ovarian Cancer Tumor Markers and Therapeutic Agents
Description of Technology: Germline mutations of BRCA1 and BRCA2
tumor suppressor genes are responsible for 5%-10% of all epithelial
ovarian cancers. However, little is known about the molecular
mechanisms involved in BRCA1 and/or BRCA2 mutation-associated (termed
BRCA-linked) ovarian carcinogenesis. To elucidate their pathways,
microarrays were used to compare gene expression patterns in ovarian
cancers associated with BRCA1 or BRCA2 mutations with gene expression
patterns in sporadic epithelial ovarian cancers to identify patterns
common to both hereditary and sporadic tumors. As a result of this
analysis, genes that are upregulated in ovarian cancer were identified.
Approximately two-thirds of the sequences identified were previously
known genes, while approximately one-third were expressed sequence
tags, representing sequences that are cloned and identified but not yet
characterized. Eighty-three genes were over-expressed in 50% of all
tumors and these over-expressed sequences may be used as markers for
ovarian cancer and/or targets for therapy.
Applications: Method to diagnose ovarian cancer; Method to treat
ovarian cancer with therapeutics that target ovarian biomarkers;
Ovarian cancer therapeutics that inhibit ovarian cancer markers such as
siRNA.
Market: Estimated 180,000 new cases of breast cancer in the U.S. in
2007; Estimated 41,000 deaths due to breast cancer in the U.S. in 2007.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Amir Jazaeri (NCI), Edison T. Liu (NCI), et al.
Publications:
1. AA Jazaeri et al. BRCA1-mediated repression of select X
chromosome genes. J Transl Med. 2004 Sep 21;2(1):32.
2. AA Jazaeri et al. Molecular determinants of tumor
differentiation in papillary serous ovarian carcinoma. Mol Carcinog.
2003 Feb;36(2):53-59.
3. AA Jazaeri et al. Gene expression profiles of BRCA1-linked,
BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002
Jul 3;94(13):990-1000.
Patent Status: U.S. Provisional Application No. 60/357,031 filed 13
Feb 2002 (HHS Reference No. E-310-2001/0-US-01); PCT Patent Application
No. PCT/US2003/046888 filed 13 Feb 2003 (HHS Reference No. E-310-2001/
0-PCT-02); U.S. Patent Application No. 10/505,680 filed 12 Aug 2004
(HHS Reference No. E-310-2001/0-US-03).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Tumor Markers in Ovarian Cancer
Description of Technology: Ovarian cancer is one of the most common
forms of neoplasia in women. Although advanced ovarian cancer has only
a 20-30% survival rate, an estimated 90% of cases are effectively
treated when detected early. However, few symptoms are associated with
early ovarian cancer, and approximately 25% of ovarian cancer cases are
diagnosed before it metastasizes. Utilizing SAGE analysis, a unique set
of ovarian cancer biomarkers has been identified that are highly
expressed in ovarian epithelial tumor
[[Page 34021]]
cells in comparison to normal ovarian epithelial cells. A better
knowledge of the mechanisms underlying ovarian tumorigenesis will
likely result in the development of novel approaches for the diagnosis
and therapy of this deadly disease.
Applications: Method to diagnose ovarian cancer; Methods to treat
patients with compositions that inhibit ovarian biomarkers such as
siRNA.
Market: Ovarian cancer is the fourth most common form of cancer in
the U.S.; Ovarian cancer is three times more lethal than breast cancer;
22,430 new cases of ovarian cancer expected in 2007; 15,280 ovarian
cancer deaths in the U.S. in 2007.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Patrice J. Morin et al. (NIA).
Related Publications:
1. KJ Hewitt, R Agarwal, PJ Morin. The claudin gene family:
expression in normal and neoplastic tissues. BMC Cancer. 2006 Jul
12;6:186.
2. PJ Morin. Claudin proteins in human cancer: promising new
targets for diagnosis and therapy. Cancer Res. 2005 Nov 1;65(21):9603-
9606.
3. R Agarwal, T D'Souza, PJ Morin. Claudin-3 and claudin-4
expression in ovarian epithelial cells enhances invasion and is
associated with increased matrix metalloproteinase-2 activity. Cancer
Res. 2005 Aug 15;65(16):7378-7385.
4. CD Hough, CA Sherman-Baust, ES Pizer, PJ Morin. Use of SAGE to
study gene expression in ovarian cancer. American Association for
Cancer Research, 9th Annual Meeting, April 10-14, 1999, Philadelphia,
Pennsylvania.
Patent Status: U.S. Provisional Application No. 60/194,336 filed 03
Apr 2000 (HHS Reference No. E-138-2000/0-US-01); PCT Patent Application
No. PCT/US2001/10947 filed 03 Apr 2001, which published as WO 01/75177
on 11 Oct 2001 (HHS Reference No. E-138-2000/0-PCT-02); U.S. Patent
Application No. 10/257,021 filed 03 Oct 2002 (HHS Reference No. E-138-
2000/0-US-03)
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301/435-4633;
wongje@mail.nih.gov.
Dated: June 8, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer,Office of
Technology Transfer,National Institutes of Health.
[FR Doc. E7-11825 Filed 6-19-07; 8:45 am]
BILLING CODE 4140-01-P
